Skip to main content
. Author manuscript; available in PMC: 2017 Nov 20.
Published in final edited form as: NPJ Vaccines. 2017 Jul 17;2:20. doi: 10.1038/s41541-017-0021-9

Fig. 3. Detection of reversion mutants of the MP-12 vaccine during viral passages in Vero cells.

Fig. 3

The MP-12 vaccine was passaged 25 times in Vero cells at MOI of 0.01 or less at three days post infection. Virus RNA was purified from culture supernatants and analyzed for the presence of reversion mutations using Taqman probes (shown in Supplementary Fig. 1 and Supplementary Table 2). (a) M-segment nt. 795: HEX-795-C and FAM-795-T, (b) M-segment nt. 3564: HEX-3564-G and FAM-3564-A, (c) L-segment nt. 533: HEX-533-C and FAM-533-T, (d) L-segment nt. 3104: HEX-3104-A and FAM-3104-G, and (e) L-segment nt. 3750: HEX-3750-A and FAM-3750-G. Two independent studies are shown (Exp-1 and 2). Relative percentages of RNA copy numbers for parental and reversion mutants are shown in blue and red bars, respectively. The bar labels in red represent the percentages of reversion mutants.